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Abstract 
Current literature addressing the pharmacological principles guiding glucocorticoid (GC) administration in ARDS is 
scant. This paucity of information may have led to the heterogeneity of treatment protocols and misinterpretation 
of available findings. GCs are agonist compounds that bind to the GC receptor (GR) producing a pharmacological 
response. Clinical efficacy depends on the magnitude and duration of exposure to GR. We updated the meta-analysis 
of randomized trials investigating GC treatment in ARDS, focusing on treatment protocols and response. We syn-
thesized the current literature on the role of the GR in GC therapy including genomic and non-genomic effects, and 
integrated current clinical pharmacology knowledge of various GCs, including hydrocortisone, methylprednisolone 
and dexamethasone. This review addresses the role dosage, timing of initiation, mode of administration, duration, and 
tapering play in achieving optimal response to GC therapy in ARDS. Based on RCTs’ findings, GC plasma concentra-
tion–time profiles, and pharmacodynamic studies, optimal results are most likely achievable with early intervention, 
an initial bolus dose to achieve close to maximal GRα saturation, followed by a continuous infusion to maintain high 
levels of response throughout the treatment period. In addition, patients receiving similar GC doses may experience 
substantial between-patient variability in plasma concentrations affecting clinical response. GC should be dose-
adjusted and administered for a duration targeting clinical and laboratory improvement, followed by dose-tapering to 
achieve gradual recovery of the suppressed hypothalamic–pituitary–adrenal (HPA) axis. These findings have practical 
clinical relevance. Future RCTs should consider these pharmacological principles in the study design and interpreta-
tion of findings.
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Introduction
The results of recently published randomized controlled 
trials (RCTs) [1, 2] provide more robust evidence sup-
porting the efficacy and safety of prolonged gluco-
corticoid (GC) treatment in acute respiratory distress 
syndrome (ARDS), despite the heterogeneity in etiologies 
and severity. GCs are agonist compounds that bind to 
the ligand-binding domain of the glucocorticoid recep-
tor (GR) to produce a biological (or pharmacological) 
response. Most anti-inflammatory effects of GCs are 
mediated through the GRα isoform. The rationale for GC 
treatment in ARDS is similar to the one for severe coro-
navirus disease 2019 (COVID-19) [3] and is reviewed 
in the Digital Supplement 1. Prolonged (≥ 7  days) low-
to-moderate dose GC treatment is an intervention 
directed at the core pathogenetic mechanisms of ARDS 
(Digital Supplement 1; Table  S1), associated with res-
cue of the cellular concentrations and functions of acti-
vated GC-GRα (Fig. 1) and mitochondria [4], exerting a 
positive effect on all “layers”—cell biology, histology, and 
physiology—of the disease process, leading to acceler-
ated disease resolution (decreased allostatic load) and 
improved short- and long-term outcomes [5].
Take‑home message 
To date there is scant literature addressing the pharmacological 
principles guiding glucocorticoid administration in ARDS. This 
review addresses how the administration mode plays a more signifi-
cant role in affecting response than the specific molecule. Dosage 
(initial, overtime, and adjustments based on response), timing of 
initiation, mode of administration, duration of therapy, tapering, and 
co-interventions to support the glucocorticoid receptor α function 
are all essential elements to achieving optimal response to therapy.
Fig. 1 Relations on natural logarithmic scales between mean levels of nuclear NF-κB and nuclear GC-GRα during the natural progression of ARDS, 
and in response to prolonged methylprednisolone treatment. Mean intracellular changes of nuclear GC-activated GRα and NF-κB were observed 
by exposing peripheral blood mononuclear cells of a healthy volunteer to ARDS patient plasma samples collected longitudinally (days 1, 3, 5, and 8) 
and after randomization to methylprednisolone treatment (randomization day (R) and post-randomization days 3, 5, 7, and 10). The mean values of 
nuclear NF-κB are plotted against the mean nuclear GC-GRα levels. Improvers had a pre-defined improvement in lung injury score [45] and/or gas 
exchange component by day 7. The left panel shows ARDS patients with adaptive and maladaptive responses. In improvers, an inverse relationship 
was observed between these two transcription factors, with the longitudinal direction of the interaction shifting leftwards (decreased NF-κB) and 
upward (increased GC-GRα). Conversely, in non-improvers, NF-κB increased over time, while GC-GRα showed no significant changes. We defined 
the first interaction as GC-GRα-driven, and the second interaction as NF-κB-driven [80]. The right panel shows non-improvers-survivors randomized 
after day 8 of ARDS to methylprednisolone (n = 11) vs. placebo (n = 6). After natural logarithmic transformation and adjustment for repeated meas-
urements, partial correlations among responses to plasma from the methylprednisolone group were − 0.92 (p < 0.0001) both for nuclear NF-κB 
and nuclear GRα. For responses to plasma from the placebo group, no significant relationship was found between nuclear NF-κB and nuclear GRα 
(r = 0.11; p = 0.70) [7]. Prolonged methylprednisolone treatment was associated with upregulation in all measurements of GC-GRα-activity leading 
to reduction in NF-κB DNA-binding and transcription of inflammatory cytokines. Glucocorticoid treatment changed the longitudinal direction 
of systemic inflammation from dysregulated (NF-κB-driven, maladaptive response) to regulated (GRα-driven, adaptive response) with significant 
improvement in indices of alveolar-capillary membrane permeability and markers of inflammation, hemostasis, and tissue repair. Reproduced with 
permission from reference [5]
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The lack of a well-defined rationale for GC treat-
ment’s critical components has resulted in consider-
able heterogeneity in the protocols investigated in 
randomized controlled trials (RCTs). While most 
pharmacological data originate from literature inves-
tigating methylprednisolone, we believe that adminis-
tration mode is more important in affecting response 
than the specific molecule. The dosage (initial, over 
time, and adjustments based on response), the timing 
of initiation, mode of administration, duration, taper-
ing, and co-interventions to support the GRα function 
are all essential elements to achieving optimal response 
to therapy. We present a summary of the pharmaco-
logical principles that should guide GC treatment in 
ARDS patients based on results of RCTs, concentra-
tion–time profiles for different dosing regimens, and 
pharmacodynamic studies. This review takes also into 
consideration recent discoveries (Digital Supplement 
1) underscoring the central regulatory function of the 
activated GRα (GC-GRα) in critical illness throughout 
disease development and resolution (Fig. 2) [4].
Pharmacological principles of glucocorticoid 
actions
Binding affinity and potency
The magnitude of the in  vitro response to the GC drug 
is proportional to the number of GR complexes, and the 
binding affinity to the receptor, and is characterized by 
the maximum response a drug is able to produce [6]. The 
concentration of GRα in cells can be increased by exoge-
nous GC administration (Digital Supplement 1) [7]. Bind-
ing affinity is expressed as relative receptor affinity (RRA), 
and dexamethasone is frequently the reference point for 
RRA with an arbitrary RRA value of 100. The RRAs for 
hydrocortisone, methylprednisolone, and dexametha-
sone are 9, 42, and 100, respectively [8]. In vivo potency 
is a measure of the concentration, usually in plasma or 
serum that is required to produce a drug response, often 
expressed as concentration required to achieve 50% of 
the maximum therapeutic effect  (EC50 or  IC50) [9]. The 
RRA of GCs is strongly correlated with the inverse of 
their  IC50 for unbound, pharmacologically active con-
centrations [8]. RRA and  IC50 are the corresponding 
in  vitro and in  vivo parameters that characterize GC 
potency and are specific to a GC agonist molecule. How-
ever, drug effects in  vivo are the result of the interplay 
Fig. 2 Glucocorticoid receptor α as a cellular rheostat of homeostatic corrections. The glucocorticoid receptor α (GRα) acts as a cellular rheostat 
to ensure that a proper response is elicited by the neuroendocrine and immune systems throughout the three phases of homeostatic corrections. 
The serial sequence of regulatory functions includes the: (1) activation and reinforcement of innate immunity (ready-reinforce), (2) downregulation 
of pro-inflammatory transcription factors (repress), and (3) promotion of disease resolution (resolve- restore).by switching production from pro-
inflammatory to pro-resolving mediators, while at the same stimulating antifibrotic and antioxidant molecules that limit tissue damage and fibrosis, 
to help achieve optimal restoration of anatomy and function of the affected tissues, and (4) parallel support of adaptive immunity. Modified with 
permission from reference.[4]. TLR2 toll-like receptor 2, purinergic receptor P2Y2R; NLRP3 NOD-like receptor pyrin containing 3, APR acute phase 
response, TF transcription factor, NF-κB nuclear factor-κB, AP-1 activator protein-1, AnxA1 annexinA1, AnxA1 receptor, ALXR A4 lipoxin receptor, GILZ 
glucocorticoid-induced leucine zipper, TGFβ transforming growth factor β
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of pharmacokinetics, i.e., the time course of the effec-
tive GC concentrations at the target site produced by the 
applied dose strength and dosing regimens, and pharma-
codynamics, i.e., the GC’s concentration–effect relation-
ship determined by its potency. Thus, a lower in vitro GC 
potency (i.e. low RRA or correspondingly high  IC50) can 
be offset clinically by higher and/or more frequent doses, 
providing higher target site concentrations.
The genomic, non-genomic and mitochondrial GC 
signaling pathways are shown in the Digital Supple-
ment 1 (Figure S1) [4]. The GC genomic effects become 
evident as early as 30  min after cytosolic GRα binding 
to positive (transactivation) or negative (cis repression) 
GC response elements (GREs) in nuclear DNA, as well 
as to mitochondrial DNA GREs (mtGRE). Moreover, 
the GC-GRα complex interacts with other transcription 
factors, such as nuclear factor-κB (NF-κB) or activator 
protein-1 (AP-1) and alters their transcriptional activi-
ties. A recent review reported on the GC regulation of 
mitochondrial transcription, via activation of mtGRE 
[10]. The degree of cytosolic GRα saturation is a direct 
modulator of the intensity of (therapeutic) GC genomic 
effects [11]. Almost complete receptor saturation can be 
achieved by a methylprednisolone-equivalent single dose 
of 80–100  mg [11]. Specific non-genomic effects (not 
mediated by induction or repression of specific genes) of 
GCs take a few minutes to be expressed, are mediated by 
plasma membrane glucocorticoid receptors, and require 
higher GC concentrations. Rapid non-genomic actions 
include, anti-inflammatory regulation, e.g., inhibition of 
neutrophil degranulation and macrophage superoxide 
anion production, and vasomotor regulation, e.g., poten-
tiation of systemic response to norepinephrine and local 
induction of endothelial nitric oxide [12, 13].
Since GRα ultimately controls GC-mediated activity, 
any condition affecting its concentration, binding affin-
ity, transport to the nucleus, GREs interaction in the 
cell nucleus and mitochondria, cofactor activity, oxida-
tive stress, or interaction with other relevant transcrip-
tion factors (NF-κB; AP-1) and co-regulators, may affect 
the cell response to GCs [14, 15]. Recent reviews have 
investigated the various ways the pro-inflammatory envi-
ronment of critical illness can negatively influence GRα 
function [15–17]. It is noteworthy that the number and 
function of the activated GRα can be modulated by the 
administration of exogenous GCs and other co-interven-
tions to improve cellular responsiveness [4]. Randomized 
studies [7, 18, 19] suggested that quantitatively adequate 
and prolonged GC supplementation increased GRα num-
ber and action in both circulating and tissue cells, revers-
ing critical illness-related corticosteroid insufficiency 
(Digital Supplement 1; Table S1).
Determinants of clinical efficacy 
Clinical efficacy depends on both pharmacodynam-
ics (i.e., potency) and pharmacokinetics [i.e., exposure 
(= magnitude and duration) of the drug at the recep-
tor site]. Together, both processes determine efficacy: 
potency + presence at the receptor site → momentary 
effect course (effect duration) → sum of momentary 
effects → clinical efficacy [20]. Mathematically, pharma-
cokinetic/pharmacodynamic models can be applied to 
describe the momentary effect–time course that stem 
from a specific GC dosing regimen. This effect–time 
course is characterized by the duration of effect (i.e., 
the time until the effect drops below a specified value), 
as well as peak magnitude. The momentary effect–time 
course can be summed up as the area under the effect–
time curve (AUETC or AUEC) or as the area between the 
baseline and effect curve (ABEC), which drive the clinical 
effect [20]. The time to reach a pharmacokinetic steady 
state is determined by the elimination half-life of the 
drug.
As most pharmacological studies evaluating GCs come 
from the rheumatology literature, the currently used 
genomic potency of natural and synthetic GCs is mainly 
based on lymphocyte proliferation suppression assays 
and may not be necessarily applicable to critical care 
[21]. Thus, a re-evaluation of genomic potency based 
on inhibition of pro-inflammatory proteins is needed. 
Dose–response studies evaluating potencies for genomic 
and non-genomic GC effects reported different values 
(Digital Supplement 1; Table S2). Non-genomic activities 
related to prostaglandin (PG)  E2 inhibition, and arachi-
donic acid release through suppression of phospholipase 
A2 synthesis were studied in 549 epithelial cell cultures. 
The cells first stimulated with IL-1β and then incubated 
for 3  h with different GC molecules [22]. Contrary to 
the classic genomic responses, epithelial cells exposed to 
methylprednisolone had a higher non-genomic response 
than those exposed to dexamethasone.
Dose–response
It has been reported that GCs have a substantially higher 
potency for genomic than non-genomic effects. There-
fore, genomic effects are usually predominant at low 
GC doses. Increasing GC doses allows the genomic 
expression modulation to reach a maximum saturation 
level quickly and then plateau off, so that further dose 
increases may largely be limited to only extending the 
duration rather than the intensity of genomic expres-
sion modulation. Depending on how genomic expres-
sion modulation is transduced into specific biomarker 
or clinical effects, GC dose increases beyond that of 
saturation level may lead to only limited further gain in 
some genomic effects at the biomarker or clinical level, 
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but may still increase in others [23]. Conversely, non-
genomic effects are usually triggered at substantially 
higher doses than genomic effects and intensify in line 
with the increasing dose until leveling off at high-dose 
therapy. Consequently, the total clinical effect as the sum 
of genomic and non-genomic effects demonstrate con-
tinuous dose-dependent increases despite saturation of 
genomic expression modulation at moderate GC dose 
levels. However, the exact relationship between GC dose, 
cellular concentrations and clinical effects remains to be 
established, especially for non-genomic effects.
ARDS randomized trials: individual concentration–time 
courses
Various GCs and dosing regimens have been used to treat 
ARDS. The treatment protocols used in ten randomized 
controlled trials (RCTs) investigating prolonged GC 
treatment in patients with early (≤ 72 h) or late (≥ 7 days) 
ARDS is shown in Digital Supplement 1 (Table S3). This 
analysis examined methylprednisolone (n = 322) [24–28], 
hydrocortisone (n = 494) [29–32], and dexamethasone 
(n = 277) [1], for a duration of therapy between 7 and 
32  days. These RCTs reported that GC treatment was 
associated with a consistent improvement in systemic 
inflammation markers and oxygenation indices, and an 
important reduction in duration of mechanical ventila-
tion (MV) and intensive care unit stay (Digital Supple-
ment 1; Table S4).
The corresponding average GC plasma concentra-
tion–time profiles expressed as methylprednisolone 
equivalents based on RRA are shown in Fig. 3. The rep-
resentation reveals substantial differences among the 
different GC dosing regimens with regard to exposure. 
Indeed, infrequent dosing (with dosing intervals of 8 or 
24  h) leads to substantial time periods without relevant 
GC serum exposure where the maintenance of GC effects 
in the target organs and tissues would be dependent on 
either persistent GC local exposure in those effect sites, 
or on mechanisms of temporal persistence of the GC 
effects beyond those periods of relevant effect site expo-
sure. Conversely, continuous administration via infusion 
maintains high exposure levels throughout the day. The 
potential disadvantage regarding the delayed onset of 
high exposure seen with infusions can be corrected with 
pre-administration of an adequate loading dose (e.g., 
methylprednisolone 1  mg/kg loading dose followed by 
a 1  mg/kg/day infusion). For non-genomic effects, it is 
important that GC exposures in treatment regimens are 
maintained at continuously high exposure levels.
While the above simulations are based on average 
pharmacokinetic parameters in healthy individuals, GC 
elimination may be impaired in ARDS patients due to 
the well-described downregulation of drug metaboliz-
ing enzymes in generalized acute inflammation [33]. 
Yates et al. reported that ARDS patients had an on aver-
age ~ 50% reduced clearance for methylprednisolone 
compared to normal values at therapy onset, which 
returned to normal values with reduction of systemic 
inflammation within a few days [34]. Correspondingly, 
methylprednisolone plasma concentrations were ele-
vated relative to healthy individuals in the early treat-
ment phase (Fig. 4). Consequently, the exposure profiles 
depicted in Fig. 3 may be viewed as a worst-case scenario, 
i.e. lowest expected exposure for GC therapy in ARDS 
patients.
Glucocorticoid administration
Factors affecting prolonged GC treatment response in 
ARDS are described in Digital Supplement 1 (Figure S2). 
There is no clear definition for the quantitation of GC 
doses used in critical illness. In most critical care stud-
ies, the hydrocortisone daily equivalent of 400 [35]—500 
[36] mg (methylprednisolone 80–100  mg, dexametha-
sone 15–18.8  mg) is used to separate low from mod-
erate doses. Based on this definition, the early ARDS 
studies shown in the Digital Supplement 1 (Table  S3), 
investigated low-to-moderate dose GC treatment. A 
daily hydrocortisone equivalent of 1500  mg (methyl-
prednisolone 300  mg, dexamethasone 56.3  mg) may be 
considered a high dose, and between 500 and 1500  mg 
hydrocortisone equivalent a moderate dose. Most of the 
data examining the effect of timing, duration, and taper-
ing is extrapolated from individual patient data (IPD) 
meta-analysis (IPDMA) of four small-to-moderate size 
(See figure on next page.)
Fig. 3 Concentration–time profiles for different dosing regimens that have been used in the treatment of early ARDS. Glucocorticoid average 
plasma concentrations were simulated on the basis of published pharmacokinetic parameters for hydrocortisone (HC), methylprednisolone 
(MP) and dexamethasone (DX) and converted to MP equivalent concentrations using their reported relative receptor affinity (RRA) and fraction 
unbound to plasma proteins (fu) [8, 9]. Pharmacokinetic parameters used for the simulations were as previously described: Clearance 18, 21, and 17 
L/h; volume of distribution 33, 64, and 103 L for HC, MP and DX, respectively. The conversion to MP equivalent concentrations for HC and DX was 
performed according to the relationship: MP equivalent plasma concentration = HC or DX concentration × (fu,HC or DX/fu,MP) × (RRA HC or DX/RRA MP). 
The applied value for RRA and  fu were 9, 42, 100 and 0.20, 0.23, 0.32 for HC, MP and DX, respectively, as previously reported [8, 9]. fu determines the 
fraction of the drug concentration that is not bound to plasma proteins and is thus available to enter cells and interact with GC receptors, i.e., the 
fraction of the concentration that is pharmacologically active
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RCTs (n = 322) investigating methylprednisolone admin-
istration in early and late ARDS [28]. There is a potential 
therapeutic advantage in treating pulmonary disorders 
with drugs that have a high penetration into affected lung 
tissue (Digital Supplement 1).
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In 2017, the Corticosteroid Guideline Task Force of 
the Society of Critical Care Medicine (SCCM) and the 
European Society of Intensive Care Medicine (ESICM) 
released guidelines for GC treatment in critically ill 
patients [35]. The Task Force applied the Grading of Rec-
ommendations Assessment, Development and Evalua-
tion (GRADE) and the Evidence-to-Decision tool making 
a conditional recommendation for GC treatment provid-
ing an on-line detailed treatment protocol (Supplemen-
tal Digital Content 5, https ://links .lww.com/CCM/C918) 
(Fig. 5) [35].
Timing
Early initiation (preferably within 6 h of diagnosis) of GC 
treatment, before homeostatic corrections reach exhaus-
tion [4] is critical in decreasing the acute and long-term 
negative impact of the allostatic load imposed during 
vital organ support. In the IPDMA, early (< 72 h) as com-
pared to late (≥ 7 days) initiation of methylprednisolone 
treatment—when fibroproliferation is still in the early 
development stage (cellular with predominant type III 
procollagen)—was associated with faster disease resolu-
tion, determined by time to extubation [hazard ratio (HR) 
3.48; 95% confidence interval (CI) 2.07–5.85 in the early 
group vs. HR = 2.06; 95% CI 1.44–2.95 in late group] and 
ICU discharge, despite a lower daily methylprednisolone 
dose (1 mg/kg/day vs. 2 mg/kg/day) [28]. Noteworthy, in 
the early ARDS RCTs, methylprednisolone was adminis-
tered as a continuous infusion. Delaying treatment and 
only administering to patients that fail to improve by the 
third day of ARDS, as proposed by some investigators, 
may miss this important window to maximize treatment 
benefit.
Initial dosage
An adequate initial loading bolus is required, particularly 
when glucocorticoids are administered as a continuous 
infusion, to achieve prompt elevation of plasma GC lev-
els and approach maximal saturation of GC receptors 
(approximately 100  mg of methylprednisolone equiva-
lent) [11] in the cytoplasm and on the cell membrane for 
genomic and non-genomic actions. A methylpredniso-
lone dose of 1 mg/kg/day in early ARDS is similar to what 
is commonly used in other forms of interstitial lung dis-
eases [37], and close to the dexamethasone dose (20 mg) 
used in the recent DEXA-ARDS RCT [1]. Experimental 
[38] and clinical research [39, 40] suggest that pulse doses 
of methylprednisolone (1000 mg/day) is not beneficial in 
ARDS.
Fig. 4 Methylprednisolone pharmacokinetics in ARDS patients. a Time-dependent increase in methylprednisolone clearance [CLt (L/Hr)] in patients 
treated with a 1 mg/kg loading dose, followed by a 1 mg/kg/day continuous infusion. The high systemic inflammatory state may be responsible for 
the impaired methylprednisolone metabolism observed in early ARDS at the beginning of therapy. High levels of pro-inflammatory cytokines are 
known to inhibit the expression and activity of hepatic drug metabolizing enzymes, including multiple cytochrome P450 isozymes relevant for the 
metabolism of methylprednisolone. Inflammation resolves progressively during continuous therapy, leading to re-establishment of homeostatic 
conditions of drug metabolizing enzyme systems. This is reflected by a time-dependent increase in methylprednisolone clearance. It took about 
2 days (41.1 h) of methylprednisolone therapy to achieve 50% of the improvement in clearance towards the re-establishment of homeostasis.[34]. 
b Methylprednisolone plasma concentration–time profile in ARDS patients receiving the aforementioned dosing regimen. Methylprednisolone 
clearance is impaired during time period 1 and its concentrations are high enough to trigger genomic and non-genomic GC effects. This most likely 
establishes initial control of the generalized inflammatory state [33]. Inflammatory control is at least partially established during period 2 within 
2 days of therapy, leading to an increased hepatic methylprednisolone clearance, secondary to re-established drug metabolizing activity. The con-
centrations are maintained around 203 ± 147 ng/mL during period 3, exerting prolonged sustained anti-inflammatory activity. Reproduced with 
permission from Yates et al. [34]. Importantly, ARDS patients receiving similar GC doses experience a substantial variability in the resulting plasma 
concentrations due to between-patient variability; this may affect nati-inflammatory response to treatment
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An in vitro study commented positively on the impact 
GC dosage has on inflammation downregulation. In 
human monocytic cells activated with graded concen-
trations of lipopolysaccharide (LPS) and then exposed to 
increasing concentrations of methylprednisolone (Digital 
Supplement 1; Figure S3), the reduction in inflamma-
tory cytokine gene (TNF-α, IL-1β, and IL-6) transcrip-
tion (irrespective of baseline inflammation severity) was 
initially modest. It then reached an inflection point, fol-
lowed by a rapid reduction, most likely related to achiev-
ing close to maximal drug receptor saturation for a 
measurable genomic and non-genomic effect [41]. This 
finding emphasizes the relevance of adequate dose selec-
tion in achieving GRα saturation and optimal results. In 
one RCT [42], the response to hydrocortisone treatment, 
based on illness severity, provides some support for this 
concept.
Mode of administration
The concentration–time profiles in Fig.  3 suggest that 
optimal GR exposure can be achieved with an initial load-
ing bolus followed by a continuous infusion (daily dose 
over 24  h) to maintain high response levels throughout 
the treatment period. Limited data show that RCTs that 
implemented this administration method [26, 27, 29, 31], 
vs. RCTs that used intermittent bolus dosing, achieved 
quicker disease resolution with more mechanical ventila-
tion (MV)-free days (Digital Supplement 2; Figures  S1). 
In patients with septic shock (3 RCTs; n = 310), there is 
no evidence for a mortality benefit between continuous 
infusion and intermittent bolus [43].
Duration of glucocorticoid administration
Duration of GC administration and tapering are main 
determinants of treatment efficacy. The role of GC treat-
ment in ARDS and critical illness is to support the central 
Fig. 5 Protocol for prolonged methylprednisolone treatment in patients with early ARDS. This protocol was recommended in the 2017 guidelines 
of the Multispecialty Task Force of the Society of Critical Care Medicine and the European Society of Intensive Care Medicine (Supplemental Digital 
Content 5, https ://links .lww.com/CCM/C918) [35] Vitamin supplementation was not part of the recommended protocol. The dosage is adjusted to 
ideal body weight and rounded up to the nearest 10 mg (e.g., 77 mg rounded up to 80 mg). Thereafter I would state that 80 mg is an example for 
a patient with an ideal body weight of 77. Day 0, intravenous bolus (80 mg in 50 cc normal saline) over 30 min. Day 0-to ICU discharge: infusion is 
done by adding the daily dosage to 240 cc of normal saline and running it at 10 cc/h. If necessary, infusion can be changed to bolus every 6 h (1/4 
daily dose) or in the last 6 days to every 12 h (1/2 daily dose). If on day 3–5 there is no improvement or even worsening oxygenation indices the 
condition is considered “unresolving ARDS”. In this case, a protocol of similar duration of treatment, but with double the daily dose of methylpred-
nisolone (starting with 160 mg/day) is initiated. If the patient is extubated before day 14, the methylprednisolone infusion is advanced to day 15 
of drug therapy and tapered according to schedule. Oral administration should be delayed to 5 days after extubation, because enteral absorption 
of methylprednisolone, and likely other GCs, is compromised for days after extubation. Rapid tapering can be associated with rebound systemic 
inflammation in the presence of suppressed adrenal function with worsening of lung physiology and an increased mortality risk [60]. If patients 
worsen significantly, then GC treatment should be restarted again, and after improvement followed by slow tapering, to comply with the Food 
and Drug Administration’s package insert warnings (Reference ID: 3,032,293) [61]. Vitamin supplementation: ascorbic acid 1.5 g every 6 h mixed in 
100 ml saline solution × 4 doses per day; thiamine 100 mg every 12 h mixed in 100 ml dextrose 5% in water × 2 doses per day; vitamin D 480,000 IU 
dose (30 ml) × 1 dose. Recheck vitamin D level on day 5; if low, supplement 96,000 IU/day for 5 days
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regulatory function played by the activated GRα in the 
acute phase (anti-inflammatory action) of the disease 
and throughout the fundamental albeit underappreciated 
phase of resolution [4]. The resolution phase is associated 
with multiple biochemical pathways, including switch-
ing production from pro-inflammatory to pro-resolving 
mediators, while also producing antifibrotic and anti-
oxidant proteins that limit tissue damage and fibrosis to 
achieve optimal restoration of anatomy and function [4, 
44].
It is essential to monitor response to treatment during 
intervention with daily assessment of lung [lung injury 
score (LIS) [45] and minute ventilation] and multiple 
organ function [Sequential Organ Failure Assessment 
(SOFA) score [46]] along with systemic inflammation 
markers [i.e., C-reactive protein (CRP)]. It sometimes 
takes two days before a CRP reduction is observed, as, 
initially, the GCs potentiate innate immunity (Fig.  2) 
[4]. Importantly, ARDS patients receiving similar GC 
doses experience a substantial variability in the resulting 
plasma concentrations due to between-patient variability 
and additional disease effects on the GC pharmacokinet-
ics, and this may affect clinical response (Fig. 4) [34]. Two 
RCTs tailored dosage and duration of therapy based on 
individual patient’s response [24, 26]. If no improvement 
was observed by day 5 or the condition worsened before 
then (Fig. 5), treatment was reset to day 1, doubling of the 
daily dose (i.e., from 80 to 160 mg methylprednisolone), 
including a new loading bolus [26]. Conversely, if the 
patient was successfully extubated (off MV > 24 h) before 
day 14, treatment was advanced to day 15. After extuba-
tion, oxygen requirements provide a simple modality to 
assess restoration of lung function. One pharmacoki-
netic study reported that intestinal methylprednisolone 
absorption is compromised for about 5 days after extu-
bation [34], and that is why switching to oral administra-
tion 5 days after MV removal may be a reasonable course 
of action. Figure 5 provides a summary of our suggested 
approach for methylprednisolone treatment.
Dexamethasone is an effective treatment in ARDS, as 
seen in the recently published DEXA-ARDS RCT [1] 
which examined moderate-to-severe ARDS and the 
RECOVERY RCT evaluating patients with COVID-
19-related ARDS [47]. A potential advantage of dexa-
methasone over alternative GCs is the single daily 
administration. The DEXA-ARDS treatment regimen 
provides a satisfactory alternative to the methylpred-
nisolone protocol. However, we believe there may be a 
potential benefit in continuing dexamethasone treatment 
following extubation and in adding a 6-to-8-day taper-
ing to the regimen (see below). Likewise, trials on hydro-
cortisone have suggested significant survival benefits in 
adults with ARDS [29–31]. Taken together these trials 
suggested that the favorable benefit to risk balance is a 
class effect.
Infection surveillance
It is essential to monitor for evidence of infection in the 
absence of fever during MV. In one RCT, infection sur-
veillance identified 56% of nosocomial infections in 
patients without fever [26]. As procalcitonin is a bacte-
rial infection biomarker that remains unaffected by GC 
treatment it is useful for early identification of infection 
[48–51], however, there is a lack of studies on ARDS 
patients receiving GC treatment. Additional infection 
monitoring parameters include an unexplained increase 
in minute ventilation (≥ 30%) or a worsening of the LIS 
or SOFA score. Unless contraindicated, surveillance 
bronchoscopic or non-bronchoscopic bronchoalveolar 
lavage (BAL) is useful for early identification of ventila-
tor-associated pneumonia and to monitor lung inflam-
mation (neutrophilia).
Tapering
Although GCs play a critical role in supporting homeo-
static corrections, this is achieved at the expense of 
reversible suppression of the hypothalamic–pitui-
tary–adrenal (HPA) axis. Unfortunately, the risk of GC 
treatment-associated adrenal suppression in critically 
ill patients with dysregulated systemic inflammation is 
underappreciated. The concept that HPA axis suppres-
sion is unlikely if GC treatment lasts less than 3  weeks 
[52] applies only to the outpatient setting and not to criti-
cally ill patients. Neither the total nor the highest dose or 
the GC treatment duration is a significant predictor of 
HPA axis recovery [53]. In the recent “Reduction in the 
Use of Corticosteroids in Exacerbated COPD (REDUCE) 
trial” that compared prednisone administration at 40 mg 
daily for 5 vs. 14 days, adrenal suppression was detected 
at hospital discharge and at thirty days in 38% and 9% of 
patients following randomization, respectively. No dif-
ferences were observed between 5 and 14  days of GC 
exposure [54]. Similarly to the experimental literature 
[55, 56], critical care RCTs have shown that abrupt GC 
discontinuation after a 3–14 days of treatment was rap-
idly followed by a rebound inflammatory response with 
severe clinical relapses in about one-third of the patients 
[25, 57–59], and a potential signal for increased mortal-
ity [25]. In the Steinberg trial [25], discontinuation of the 
study drug (administered as intermittent boluses) within 
48  h of successful extubation was associated with clini-
cal relapse in one-quarter of methylprednisolone-treated 
patients. These patients necessitated a return to MV and 
did not receive a re-institution of GC treatment. This 
led to poor outcomes with additional days of MV and a 
nine-fold increased risk of 60-day mortality (p = 0.001), 
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as compared to patients that did not return to MV [60]. 
In patients with sepsis with or without ARDS evidence 
for clinically significant rebound after termination of 
corticosteroids without tapering is missing [43]. Gradual 
tapering may (1) preserve the improvements achieved 
during GC administration, (2) sustain continuous reso-
lution and restoration of tissue homeostasis, (3) achieve 
gradual recovery of the suppressed HPA axis, (4) forestall 
disease relapse from rebound systemic inflammation, and 
(5) complies with the Food and Drug Administration’s 
package insert warnings (Reference ID: 3032293) [61].
Co‑interventions
The activated GRα interdependence with functional 
mitochondria and essential vitamin reserves provides a 
rationale for co-interventions that include prolonged GC 
treatment in association with rapid correction of hypo-
vitaminosis to improve cellular responsiveness. Oxidative 
stress has a direct deleterious impact on GR number and 
function [4]. Three vitamins, i.e. thiamine (vitamin B1), 
ascorbic acid (vitamin C), and vitamin D, are important 
for the proper functioning of the GR system and mito-
chondria, but their reserves are rapidly exhausted in 
critical illness [62]. A comprehensive list of suggested 
mechanisms for the efficacy of thiamine, ascorbic acid, 
and GCs in critical illness, and an updated rationale for 
the co-intervention were recently reviewed [4, 63]. The 
impact Vitamin C has on activated GRα activity is shown 
in the Digital Supplement 1 (Figure S4) [4]. A recent RCT 
on patients with sepsis-associated ARDS reported a pos-
sible reduction in 28-day all-cause mortality, although 
as this was a secondary outcome, it was under-powered 
[64]. However, other potential co-interventions directed 
at increasing GR expression, e.g., statins [65], melatonin 
[66], beta-blockers [67], calcium channel blockers [67], 
or directed at improving mitochondrial function [68–70] 
have not been investigated in association either with GC 
treatment in acute illness or alone in chronic critical 
illness.
Clinical efficacy
Digital Supplement 2; Figures  S3, S4, and S5 report the 
impact of prolonged GC treatment on the outcomes of 
duration of mechanical ventilation, length of ICU stay, 
and hospital mortality (relative risk 0.65; 95% confidence 
interval 0.50–0.85—number needed to save one life: 7.2). 
Importantly, the survival benefit observed during hos-
pitalization persisted after hospital discharge with fol-
low-up observations extending up to 60 days [1, 29, 42], 
4 months [24], 6 months [25], or one year (limit of meas-
urement) [26]. Survival rates at 2, 6, and 12 months were 
76% vs. 61% (p-value = 0.13), 67% vs. 46% (p value = 0.07), 
and 63.5% vs. 46% (p value = 0.13), respectively [26]. In 
aggregate data from four RCTs in patients (n = 945) hos-
pitalized with community-acquired pneumonia, early ini-
tiation of GC treatment prevented progression to ARDS 
(n = 945; 0.4% vs. 3.0%; RR 0.27, 95% CI 0.08, 0.87) [71]. 
Recent RCTs in COVID-19 patients provide additional 
support for prolonged GC treatment in early ARDS. 
Rationale for GC treatment in severe COVID-19 was 
recently reviewed [72]. A prospective meta-analysis of 
seven RCTs investigating critically ill adults with COVID-
19 (n = 1703) reported a significant reduction in 28-day 
mortality (32.7% vs.41.5%; OR 0.66, 95% CI, 0.53–0.82). 
There were no differences in survival benefit between 
the three corticosteroids investigated (dexamethasone 
for 10 days, hydrocortisone for 7 or 14 days, and meth-
ylprednisolone for 5 days), and no evidence for increased 
risk of serious complications [2]. These findings led the 
World Health Organization to recommend GC treatment 
for severe COVID-19 [73].
Therapeutic index
The therapeutic index is a measure of drug safety. Except 
for transient hyperglycemia (mostly within 36  h after 
an initial bolus), GC treatment is not associated with a 
higher risk of neuromuscular weakness, [74] gastrointes-
tinal bleeding, or nosocomial infection (Digital Supple-
ment 2; Figure S6). Moreover, GC treatment-associated 
downregulation of systemic and pulmonary inflammation 
might lower the risk of developing nosocomial infections 
by (1) decreasing MV duration, (2) achieving an inflam-
matory milieu less favorable for intra- and extra- cellular 
growth of the bacterial pathogens frequently encoun-
tered in ARDS (Staphylococcus aureus, Pseudomonas 
aeruginosa, and Acinetobacter sps.) [75], and (3) improv-
ing opsonization-dependent phagocytic neutrophil func-
tion [76] and intracellular killing [41]. Inflammation has 
a bidirectional effect on the growth of nosocomial path-
ogens; lower inflammatory cytokine levels—similar to 
values detected in ARDS survivors—suppress growth, 
whilst higher levels—similar to values detected in ARDS 
nonsurvivors—enhance bacterial growth in a dose-
dependent manner [75]. In LPS-activated immune cells 
exposed to graded doses of methylprednisolone, con-
centrations similar to the plasma levels (150–250 μg/ml) 
achieved in ARDS patients on methylprednisolone infu-
sion (1  mg/kg/day) [34] were associated with the most 
significant reduction in intracellular bacterial growth and 
TNF-α, IL-1β, and IL-6 gene expression.[41]
The endothelial GRα is a critical regulator of vascu-
lar homeostatic corrections, and essential for restoring 
the integrity of the blood–brain barrier [4]. In ARDS 
survivors, longer GC treatment was associated with 
lower anxiety scores (p value = 0.019) and a trend (p 
value = 0.05) for improvement in post-traumatic stress 
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syndrome score symptomatology [77], similar to the 
improvements previously reported in patients with septic 
shock [78].
Conclusions and future directions
To the best of our knowledge, this is the first review 
examining the pharmacological principles guiding GC 
treatment in ARDS which examines how each compo-
nent of the treatment protocol is relevant to achieve opti-
mal results. We suggest that future RCTs evaluating GC 
treatment in ARDS should consider these pharmacologi-
cal principles in their design and protocol. RCTs compar-
ing how different GC doses and duration of treatment 
impact on laboratory markers of inflammation and oxy-
genation, duration of mechanical ventilation, and short- 
and long-term morbidity and mortality have important 
clinical relevance. An effort is in progress to best char-
acterize subphenotypes in ARDS [79], to identify those 
more likely to benefit from an intervention. An approach 
based on these pharmacological principles may help to 
eventually personalize GC treatment protocols based on 
patients’ individual clinical and laboratory characteristics 
with longitudinal adjustments directed by measurement 
of physiological and laboratory markers.
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